An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer

Value in Health

Volumn 14, Issue 2, 2011, Pages 274-281

  Vissers, Debby C J ^a   Lenre, Malin ^b   Tolley, Keith ^c   Jakobsson, Jan ^d   Sendersky, Veronica ^b   Jansen, Jeroen P ^e  

^a MAPI GROUP   (Netherlands)

^b Tolley Health Economics Ltd ^*

^c Tolley Health Economics Ltd   (United Kingdom)

^d KAROLINSKA INSTITUTE   (Sweden)

^e MAPI VALUES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABSTRAL; FENTANYL; FENTANYL CITRATE; OPIATE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER PAIN; CANCER PATIENT; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG EFFICACY; HUMAN; PAIN ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; SWEDEN; VALIDATION PROCESS;

EID: 79959577835     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2010.09.007     Document Type: Article

References (32)

1. Portenoy RK, Forbes K, Lussier D, et al. Difficult pain problems: An integrated approach. In: Doyle D, Hanks G, Cherny N, et al., eds. Oxford Textbook of Palliative Medicine (3rd ed.). London: Oxford University Press, 2004.
2. Zeppetella G. Opioids for cancer breakthrough pain: A pilot study reporting patient assessment of time to meaningful pain relief. J Pain Symptom Manage 2008;35:563-7.
3. Gómez-Batiste X, Madrid F, Moreno F, et al. Breakthrough cancer pain: Prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manage 2002;24:45-52.
4. Svendsen KB, Andersen S, Arnason S, et al. Breakthrough pain in malignant and non-malignant diseases: A review of prevalence, characteristics and mechanisms. Eur J Pain 2005; 9:195-206. (Pubitemid 40311842)
5. Breivik H, Cherny N, Collett B, et al. Cancer-related pain: A pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol 2009;20:1420-33.
6. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: Characteristics and impact in patients with cancer pain. Pain 1999;81:129-34. (Pubitemid 29199908)
7. Zeppetella G, O'Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage 2000;20:87-92.
8. Caraceni A, Martini C, Zecca E, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 2004;18:77-83.
9. Green CR, Montague L, Hart-Johnson TA. Consistent and breakthrough pain in diverse advanced cancer patients: A longitudinal examination. J Pain Symptom Manage 2009;37: 831-47.
10. Abernethy AP, Wheeler JL, Fortner BV. A health economic model of breakthrough pain. Am J Manag Care 2008; 14(5 Suppl. 1):S129-40. (Pubitemid 351786787)
11. Fortner BV, Okon TA, Portenoy RK. A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain 2002;3:38-44. (Pubitemid 34163489)
12. Fortner BV, Demarco G, Irving G, et al. Description and predictors of direct and indirect costs of pain reported by cancer patients. J Pain Symptom Manage 2003;25:9-18. (Pubitemid 36149734)
13. Davies AN, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain: Recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 2009;13:331-8.
14. Farrar JT, Cleary J, Rauck R, et al. Oral transmucosal fentanyl citrate: Randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 1998;90:611-6. (Pubitemid 28204805)
15. Portenoy RK, Taylor D, Messina J, et al. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006;22:805-11. (Pubitemid 44627444)
16. Slatkin NE, Xie F, Messina J, et al. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 2007;5:327-34. (Pubitemid 350055013)
17. Kress HG, Oroń ska A, Kaczmarek Z, et al. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 μg for breakthrough pain in patients with cancer: A phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther 2009;31:1177-91.
18. Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: A randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001;91:123-30. (Pubitemid 32274181)
19. Mercadante S, Radbruch L, Davies A, et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: An open-label, randomised, crossover trial. Curr Med Res Opin 2009;25:2805-15.
20. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: Combining direct and indirect evidence. BMJ 2005;331:897-900. (Pubitemid 41502718)
21. Lu G, Ades AE, Sutton AJ, et al. Meta-analysis of mixed treatment comparisons at multiple follow-up times. Stat Med 2007;26:3681-99. (Pubitemid 47307743)
22. Jansen JP, Crawford B, Bergman G, et al. Bayesian metaanalysis of multiple treatment comparisons: An introduction to mixed treatment comparisons. Value Health 2008;11:956-64.
23. Vissers DCJ, Nolte T, Stam WB, et al. Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer. Curr Med Res Opin 2010;26:1037-45.
24. Jensen MP, Karoly P, Braver S. The measurement of clinical pain intensity: A comparison of six methods. Pain 1986;27: 1147-126.
25. Downie WW, Leatham PA, Rhind VM, et al. Studies with pain rating scales. Ann Rheum Dis 1978;37: 378-81. (Pubitemid 9017965)
26. Kremer E, Atkinson JH, Ignelzi RJ. Measurement of pain: Patient preference does not confound pain measurement. Pain 1981;10:241-8. (Pubitemid 11096921)
27. Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986;5:1-30. (Pubitemid 16098443)
28. Tandvårds-och läkemedelsförmånsverket, Welcome to the Dental and Pharmaceutical Benefits Agency. Available from: Http://www.tlv.se/beslut/sok/lakemedel/ [Accessed April, 2, 2009].
29. Zethraeus N, Borgström F, Jönsson B, et al. Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: Results based on the Women's Health Initiative randomized controlled trial. Int J Technol Assess Health Care 2005;21:433-41. (Pubitemid 41642834)
30. Song F, Altman DG, Glenny AM, et al. Validity of indirect comparison for estimating efficacy of competing interventions: Empirical evidence from published metaanalyses. BMJ 2003;326:472.
31. Hauber AB, McCrink L, Beard S, et al. Population health state utilities for fibromyalgia in the United Kingdom. Value Health 2008;11:A353.
32. Wolfe F. HAQ-based utilities and SF6D systematically overvalue quality of life (QoL) in RA patients with severe RA, pain and psychological distress. Arthritis Rheum 2003;48; (Suppl. 9):S399.